[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"malignant-pleural-mesotheliomas\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:malignant-pleural-mesotheliomas":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":5},"100632217","phase-1-dual-target-mslnfap-car-nk-cells-for-pleural-and-peritoneal-mesothelioma-100632217",false,"NCT07510815","Dual-Target MSLN\u002FFAP CAR-NK Cells for Pleural and Peritoneal Mesothelioma","A Phase 1\u002F2, Open-Label, Nonrandomized, Biomarker-Guided Study of Locoregional Allogeneic Dual-Target Mesothelin (MSLN) \u002F Fibroblast Activation Protein (FAP) Chimeric Antigen Receptor Natural Killer Cells in Adults With Unresectable, Recurrent, or Refractory Pleural or Peritoneal Mesothelioma","DUAL-MESO-NK","Inclusion Criteria:\n\n* Age 18 to 75 years at the time of consent.\n* Histologically confirmed malignant pleural mesothelioma or malignant peritoneal mesothelioma; unresectable, recurrent, metastatic, or refractory disease.\n* Prior receipt of at least one standard systemic regimen for mesothelioma, or documented ineligibility, intolerance, or refusal of standard therapy considered reasonable by the investigator.\n* Central biomarker confirmation of MSLN-positive tumor cells and FAP-positive tumorassociated stroma at protocol-defined thresholds.\n* At least one measurable or evaluable lesion by cohort-appropriate imaging criteria.\n* ECOG performance status 0 to 1.\n* Adequate bone marrow, renal, hepatic, coagulation, cardiac, and pulmonary function to undergo lymphodepletion and locoregional cell infusion.\n* Safe procedural access for intrapleural or intraperitoneal administration, as applicable.\n* Recovery to Grade 1 or better from prior anticancer therapy toxicities, except alopecia, stable neuropathy, or controlled endocrine replacement.\n* Life expectancy of at least 12 weeks.\n* Negative pregnancy test for participants of childbearing potential and agreement to use protocoldefined contraception.\n* Ability to understand and sign informed consent\n\nExclusion Criteria:\n\n* Active or untreated CNS metastases, leptomeningeal disease, or uncontrolled seizures.\n* Uncontrolled bacterial, fungal, viral, or mycobacterial infection, including empyema, active pleural space infection, peritonitis, or uncontrolled HBV, HCV, or HIV infection.\n* Autoimmune disease requiring systemic immunosuppression within 14 days before lymphodepletion, or prednisone equivalent greater than 10 mg\u002Fday.\n* Clinically significant cardiovascular disease, uncontrolled arrhythmia, unstable angina, recent myocardial infarction, or other condition judged to increase infusion risk.\n* Severe interstitial lung disease, baseline oxygen requirement, or other pulmonary compromise making pleural therapy unsafe.\n* Bowel perforation risk, uncontrolled bowel obstruction, uncontrolled ascites, or any abdominal condition that makes intraperitoneal infusion unsafe in the peritoneal cohort.\n* Prior gene-modified cell therapy directed against MSLN or FAP within the protocol washout period, or active graft-versus-host disease after prior transplant.\n* Need for concurrent systemic anticancer therapy other than protocol-permitted supportive care.\n* Pregnancy or breastfeeding.\n* Any medical, psychiatric, social, or logistical condition that, in the investigator's judgment, could compromise safety, compliance, or interpretability of study results.","ALL","18 Years","75 Years",{"count":21,"type":22},36,"ESTIMATED","INTERVENTIONAL",[25,26],"PHASE1","PHASE2","This example study evaluates locoregional allogeneic dual-target mesothelin\u002FFAP CAR-NK cells in adults with unresectable, recurrent, or refractory pleural or peritoneal mesothelioma.\n\nEligible participants must have central confirmation of MSLN-positive tumor cells and FAP-positive tumorassociated stroma. The phase 1 portion defines the recommended phase 2 dose and schedule, and the phase 2 expansion explores preliminary antitumor activity, persistence, and biomarker response in pleural and peritoneal disease cohorts.",[29],"Malignant Pleural Mesotheliomas",[31,32,33,34,35,36,37,38],"Mesothelioma","Pleural Mesothelioma","Peritoneal Mesothelioma","MSLN","FAP","Dual-Target CAR-NK","Locoregional Cell Therapy","Solid Tumor Immunotherapy","RECRUITING","2026-03-31",{"date":42,"type":43},"2026-04-06","ACTUAL",{"date":45,"type":43},"2026-03-02",{"date":47,"type":22},"2028-04-17",{"name":49,"class":50},"Beijing Biotech","INDUSTRY"]